
==== Front
Curr Neuropharmacol
Curr Neuropharmacol
CN
Current Neuropharmacology
1570-159X
1875-6190
Bentham Science Publishers

38073106
CN-22-1391
10.2174/1570159X22999231207105743
Medicine, Neurology, Pharmacology, Neuroscience
Biphasic Hormetic-like Effect of Lebecetin, a C-type Lectin of Snake Venom, on Formalin-induced Inflammation in Mice
Belardo Carmela 1#
Jebali Jed 2#
Boccella Serena 1#
Infantino Rosmara 1
Fusco Antimo 1
Perrone Michela 1
Bonsale Roozbe 1
Manzo Iolanda 1
Iannotta Monica 1
Scuteri Damiana 3*
Ferraraccio Franca 4
Panarese Iacopo 4
Ferrara Giovanna 4
Guida Francesca 1
Luongo Livio 1
Palazzo Enza 1
Srairi-Abid Najet 2
Marrakchi Naziha 2
Maione Sabatino 1*
1 Department of Experimental Medicine, Pharmacology Division, University of Campania “L. Vanvitelli”, Naples, Italy;
2 Laboratory of Biomolecules, Venoms and Theranostic Applications, LR20IPT01, Institut Pasteur of Tunis, University of Tunis El Manar, Tunis 1002, Tunisia;
3 Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy;
4 Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania “L. Vanvitelli”, Naples, Italy
* Address correspondence to these authors at the Department of Experimental Medicine, Pharmacology Division, University of Campania “L. Vanvitelli”, Naples, Italy; Tel: +390815667650; Fax: 390815667650; E-mail: sabatino.maione@unicampania.it and Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy; Tel: +39 0984/493462; E-mail: damiana.scuteri@unical.it
# The authors Carmela Belardo, Jed Jebali, and Serena Boccella share first authorship.
08 12 2023
2024
22 8 13911405
14 12 2022
21 3 2023
23 3 2023
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Background

Integrins, important extracellular matrix (ECM) receptor proteins, are affected by inflammation and can participate in the maintenance of many painful conditions. Although they are ubiquitous and changeable across all cell types, the roles of these cell adhesion molecules in pathological pain have not been fully explored.

Objectives

We evaluated the effects of the subcutaneous injection of lebecetin, a C-type lectin isolated from Macrovipera lebetina snake venom, previously reported to inhibit α5β1 and αv integrin activity, on different components of inflammation induced by the formalin administration in the hind paw of mice.

Methods

The formalin-induced nocifensive behavior, edema, and histopathological changes in the hind paw associated with cytokine, iNOS, and COX2 expression, nociceptive-specific neuron activity, and microglial activation analysis in the spinal cord were evaluated in mice receiving vehicle or lebecetin pretreatment.

Results

Lebecetin inhibited the nocifensive responses in the formalin test, related edema, and cell infiltration in the injected paw in a biphasic, hormetic-like, and dose-dependent way. According to that hormetic trend, a reduction in pro-inflammatory cytokines IL-6, IL-8, and TNF-alpha and upregulation of the anti-inflammatory cytokine IL-10 in the spinal cord were found with the lowest doses of lebecetin. Moreover, COX2 and iNOS expression in serum and spinal cord followed the same biphasic pattern of cytokines. Finally, nociceptive neurons sensitization and activated microglia were normalized in the dorsal horn of the spinal cord by lebecetin.

Conclusion

These findings implicate specific roles of integrins in inflammation and tonic pain, as well as in the related central nervous system sequelae.

Keywords

Snake venom
lebecetin
integrins
formalin
inflammation
pain
mice
==== Body
pmc1 INTRODUCTION

Poisons derived from animals, such as snakes, scorpions, spiders, wasps, frogs, and many others, have gained increasing interest in recent years. Specific structural modifications using biotechnological techniques have made possible a pharmacological application for some of these toxins in various areas of medicine [1, 2]. A modified form of chlorotoxin, a peptide isolated from the scorpion venom Leiurus quinquestriatus, has been tested for some forms of astroglioma in humans [3, 4]. Ziconotide, a synthetic analog of a peptide found in the venom of the marine snail Conus magus, which blocks presynaptic N-type calcium channels in the spinal cord, is currently approved for severe chronic pain resistant to strong opioids [5]. More impactful was the introduction of exenatide, a synthetic analog of exendin-4 isolated from the saliva of the Gila monstrous lizard, for the treatment of diabetes mellitus [6, 7]. Therefore, despite the high toxicological properties of venoms, many peptides derived from animal venom paradoxically show therapeutic potential as thrombolytic, antiplatelet, and antiangiogenic agents , associated with anti-metastatic and anti-proliferative effects [8].

The venom of the Macrovipera lebetina is an amalgam of different proteins, including proteases, phosphodiesterases, phosphatases, phospholipase A2, disintegrins, and C-type lectin-like proteins [8-14]. Among the C-type lectin-like proteins from Macrovipera lebetina, lebectin and lebecin, showed a powerful inhibition of platelet aggregation, cell adhesion, migration, invasion, and proliferation by inhibiting the α5β1 and αv integrins without inhibition of the collagen α2β1 receptor [15, 16]. Another C-type lectin-like protein isolated from the same venom lebecetin displayed anti-integrin activity by inhibiting the α5β1 and αv integrins [15, 17]. Lebecetin showed some pharmacological effects, including i) inhibition of thrombin- and collagen-induced platelet aggregation [18, 19], ii) inhibition of adhesion, migration, and proliferation of tumor and microvascular endothelial cells [17], and iii) inhibition of choroidal and retinal neovascularization [20]. Lebecetin also shaped the inflammatory response in vitro by inhibiting the pro-inflammatory cytokines TNF-α, IL-6, and IL-8 or stimulating the expression of the anti-inflammatory cytokine IL-10 following exposure to the bacterial lipopolysaccharide, LPS, in human THP-1-derived macrophages. This effect was associated with an inhibition of ERK1/2, p38, AKT kinases, NF-κB, and αvβ3 integrin expression [21]. Despite various biological activities, including a potential anti-inflammatory effect of lebecetin, and evidence demonstrating that integrins have a role in inflammatory or neuropathic pain [22], the analgesic and anti-inflammatory effect of lebecetin in vivo has not yet been investigated. Injection of formalin into the hind paw of rodents induces inflammatory pain, which allows monitoring of both, acute and tonic pain responses and the underlying inflammatory, neurogenic, and central mechanisms of nociception [23-25]. On this basis, the current study aims to investigate the effect of lebecetin on nocifensive responses, paw edema, and histopathological features induced by the administration of formalin into the hind paw. The effects of lebecetin on formalin-induced neuronal sensitization, microglia changes, iNOS, COX2, and pro-inflammatory/anti-inflammatory cytokines expression in the dorsal horn of the spinal cord were also investigated. Hopefully, these data will highlight the potential therapeutic application of C-type lectin-like biomolecules in the management of inflammatory lesions with an important painful component involved in the development and progression of several diseases.

2 MATERIALS AND METHODS

2.1 Animals

Adult male C57/BL6J mice (Envigo, Milan, Italy), weighing 22-25 g, were housed in 3 per cage under controlled illumination (12:12 hr light-dark cycle; light on 6.00 a.m.) and standard environmental conditions (ambient temperature 20-22°C, humidity 55-60%) for at least 1 week before the commencement of experiments. Mouse chow and tap water were available ad libitum. The experimental tests were carried out during the light phase. The experimental procedures were approved by the Animal Ethics Committee of the University of Campania “L. Vanvitelli” (Naples, Italy). Animal care complied with Italian (D.L. 116/92) and EEC (O.J. of E.C. L358/1 18/12/86) regulations on the protection of laboratory animals. All efforts were made to minimize animal suffering and reduce the number of animals used.

2.2 Formalin Test

Each mouse was randomly assigned to one of the experimental groups, placed in a plastic cage, and allowed to move freely for 30 min. A mirror was placed at a 45° angle under the cage to allow a full view of the hind paws. Vehicle (PBS, 1%, 30 μl) or different doses of lebecetin (0.15, 0.32, 0.64, and 1.31 nmol in 30 μl) were subcutaneously administered 10 min before injecting formalin (1.25%, 30 μl) into the dorsal surface of the hind-paw. Lifting, licking, shaking, and flinching of the injected paw were recorded as nocifensive responses. Recording of nocifensive behavior scored in 5-min blocks was commenced immediately after the injection of formalin and was continued for 60 min. Groups of 7-10 mice per treatment were used, with each animal used for one treatment only. Results were expressed as mean ± S.E.M. of the total time spent in nocifensive response in min.

2.3 Determination of Edema Formation

The hind paw edema in mice was measured before (0 h) and at 60 minutes after formalin injection into the dorsal surface of the hind paw using an analogic caliper (Stainless Steel Digital Caliper, Bay, Gaithersburg, MD, USA). Data were recorded and expressed as mean ± S.E.M. of paw thickness in mm to the nearest ± 0.01 mm.

2.4 In Vivo Single-unit Electrophysiological Recordings of Spinal Nociceptive-specific Neurons

For in vivo single unit extracellular recording, mice were anesthetized with avertin (1.25%). After tracheal cannulation, a catheter was placed into the right external jugular vein to allow a continuous further infusion of propofol (5-10 mg/kg/h, i.v.). Spinal cord L4-L6 segments were exposed medially by laminectomy, near the dorsal root entry zone, up to a depth of 1 mm. Mice were then secured in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, United States) supported by clamps attached to the vertebral processes on either side of the exposure site. An elliptical rubber ring (about 3 mm × 5 mm) was tightly sealed with silicone gel onto the surface of the spinal cord. This ring formed a depression that provided access to spinal neurons receiving input from the ipsilateral paw, where formalin, vehicle, or solutions containing different doses of lebecetin were injected. The exposed area of the spinal cord was framed with agar and then filled with mineral oil. Body temperature was maintained at 37°C with a temperature-controlled heating pad. A glass-insulated tungsten filament electrode (3-5 MΩ; FHC Frederick Haer& Co., Bowdoin, ME, United States) was used to record the single-unit extracellular activity of dorsal horn nociceptive-specific (NS) neurons. NS neurons were defined as those neurons that respond only to high-intensity (noxious) stimulation. To confirm NS neuron response patterns, each neuron was characterized while applying mechanical stimulation to the ipsilateral hind paw using a von Frey filament with 97.8 mN bending force (noxious stimulation) for 2 s until it buckled slightly. Only neurons that responded specifically to the noxious hind paw stimulation without responding to stimulation of the surrounding tissue were considered. The recorded signals were amplified and displayed on a digital storage oscilloscope to ensure that the unit under study was unambiguously discriminated throughout the experiment. Signals were also fed into a window discriminator, whose output was processed by an interface CED 1401 (Cambridge Electronic Design Ltd., Milton, United Kingdom) connected to a Pentium III PC. Spike2 software (CED, version 4) was used to create peristimulus rate histograms online and to store and analyze digital records of single-unit activity offline. Configuration, shape, and height of the recorded action potentials were monitored and recorded continuously using a window discriminator and the Spike2 software for online and offline analysis. This study included only neurons whose peak configuration remained constant and discriminated against background activity, thus allowing the activity of a single neuron and the same neuron to be analyzed throughout the experiment. The spontaneous and noxious-evoked neuronal activity was expressed as spikes/s (Hz) for the spontaneous activity and frequency of excitation and in seconds (s) for the duration of excitation. At the end of the experiment, each animal was sacrificed with a lethal dose of urethane.

2.5 Immunoassays (ELISA)

Enzyme-linked immunosorbent assays (ELISAs) were performed to analyze the levels of proinflammatory and antiinflammatory cytokines (IL1β, IL-6, IL-8, IL-10, and TNF-α) in the spinal cord and COX2 and iNOS enzymes in the spinal cord and serum (Elabscience, Houston, ID, USA). Tissue samples of the spinal cord were weighed and homogenized in PBS 0.01M pH = 7.4 (tissue weight (g): PBS ml = 1:9). The homogenates were centrifuged for 5-10 min at 5000 × g at 4°C to get the supernatant. The serum was also collected and left to clot overnight at 2-8°C before centrifugation for 20 min at 1000×g at 2-8°C. The supernatant was collected to carry out the assay.

2.6 Immunofluorescence

Under anesthesia, mice were transcardially perfused with a saline solution followed by 4% paraformaldehyde in 0.1 M phosphate buffer. The lumbar spinal cord was excised, post-fixed for 4 h in the perfusion fixative, cryoprotected for 72 h in 20% sucrose in 0.1 M phosphate buffer and frozen in O.C.T. embedding compound. Transverse sections (20 micrometers) were cut using a cryostat and thaw-mounted onto glass slides. Slides were incubated overnight with primary antibody solutions for the microglial cell marker Iba-1 (rabbit anti-ionized calcium-binding adapter molecule 1; 1:1000; Wako Chemicals, Germany). Following incubation, sections were washed and incubated for 3 h with a secondary antibody solution (goat anti-rabbit, IgG-conjugated Alexa FluorTM 488; 1:1000; Molecular Probes, USA). Slides were washed, cover-slipped with Vectashield mounting medium (Vector Laboratories, USA) and visualized under a Leica fluorescence microscope.

The numbers of profiles positive for each marker were determined within a box measuring 104 um2 in the lateral, central, and medial areas of the dorsal horn spinal cord sections. Eight L5 spinal sections were evaluated from each of the three mice per group. An average value obtained by combining the values of the lateral, central, and medial areas of both dorsal and ventral horns was considered. Mean values for three mice per group were then compared using one-way ANOVA followed by Tukey’s post hoc test. P < 0.05 was set as the level of statistical significance.

2.7 Histopathology Examination

For histological examination, biopsies of the hind paws were taken 60 min following the subcutaneous administration of formalin. All tissue samples were fixed in 10% neutral buffered formalin solution, embedded in paraffin wax, cut into 10 μm thick sections, and stained with hematoxylin-eosin. All samples were photographed with a Canon EOS700 camera connected to an optical microscope.

2.8 Drugs

Venom was collected from M. lebetina snake in the serpentarium of the Pasteur Institute of Tunisia. Lebecetin was purified to homogeneity from M. lebetina venom by gel filtration on a Sephadex G75 column followed by ion exchange chromatography on a Mono S column and characterized as previously described [18]. The lyophilized lebecetin was dissolved in PBS at a concentration of 1.31 nmol (stock solution) and subsequently diluted at 0.15, 0.32, 0.64, and 1.31 nmol in 30 microliters. A 10% formalin solution was purchased from Sigma-Aldrich, St Louis, MO, USA and diluted at 1.25% in 30 ml.

2.9 Statistics

Data were represented as mean ± SEM. Behavioral data were analyzed by two-way ANOVA followed by Dunnet's post-hoc test. Paw thickness and in vitro data were analyzed by one-way ANOVA followed by Dunnett’s post-hoc test. Iba-1 immunoreactivity was analyzed by one-way ANOVA followed by Tukey’s post hoc test. Electrophysiological recording data were analyzed by two-way ANOVA followed by Tukey’s post-hoc test. P values < 0.05 were considered statistically significant. Statistical analysis was carried out using Prism/Graphpad (GraphPad Software, Inc.) software.

3 RESULTS

3.1 Effect of Different Doses of Lebecetin on Formalin-induced Nocifensive Behavior

In mice that received the subcutaneous injection of vehicle (veh, PBS 1%, 30 μl) 10 min before formalin (Form, 1.25%, 30 μl) in the dorsal surface of the hind paw, the first phase of noxious behavior lasting for 0-10 min was observed immediately after the injection of formalin. The nocifensive behavior in the first phase was 3.08 ± 0.18 min. This phase was followed by a second phase of nociceptive behavior, reflecting the development of nociceptive sensitization in the dorsal horn of the spinal cord [24, 26]. The nocifensive behavior in the second phase was 2.09 ± 0.63 min at 30 min after formalin administration. Subcutaneous administration of the lowest doses of lebecetin (Lebe, 0.15 nmol and 0.32 nmol in 30 μl) 10 min before the formalin administration reduced the nocifensive behavior in the first phase (1.22 ± 0.09 min and 2.03 ± 0. 19 min, respectively). Such doses of lebecetin (0.15 nmol and 0.32 nmol in 30 μl) also reduced the second phase of nocifensive behavior (0.56 ± 0.10 min and 0.23 ± 0.1 min, respectively). Higher doses of lebecetin (0.64 nmol and 1.31 nmol in 30 μl) did not modify the nocifensive behavior in the first phase (1.94 ± 0.32 min and 2.24 ± 0.29 min, respectively), while they reduced the nocifensive behavior in the second phase of the formalin test (0.63 ± 0.17 min and 0.91 ± 0.22 min, respectively) compared to vehicle-injected mice (Fig. 1A). The dose-response curve of different doses of lebecetin in formalin-injected mice is presented in Fig. (1B).

3.2 Effect of Different Doses of Lebecetin on Formalin-induced Paw Edema

In mice that received the subcutaneous injection of vehicle (Veh, PBS 1% in 30 μl) in the dorsal surface of the hind paw, the paw thickness was 0.3 ± 0.05 mm. The administration of formalin (1.25%, 30 μl) increased the paw thickness (1.93 ± 0.06 mm) compared to the paw thickness of mice that received the vehicle. The administration of the different doses of lebecetin (Lebe, 0.15, 0.32, 0.64, and 1.31 nmol in 30 μl) 10 min before the formalin reduced the paw thickness (0.3 ± 0.05 mm, 0.46 ± 0.03 mm, 0.66 ± 0.12 min, and 0.9 ± 0.05 mm, respectively) compared to the paw thickness of mice that received the administration of vehicle 10 min before the administration of formalin (Fig. 1C).

3.3 Effect of Lebecetin on Spinal NS Neuron Activity

The administration of the vehicle into the hind paw did not affect the spontaneous activity (0.035 ± 0.03 spikes/s), frequency of excitation (15.46 ± 0.44 spikes/s), and the duration of excitation (2.20 ± 0.071 s) of spinal NS neurons compared to respective pre-administration values (0.04 ± 0.005 spikes/s, 15.53 ± 0.36 spikes/s, and 2.12 ± 0.075 s) (Fig. 2). The administration of formalin (1.25%, 30 ul) into the dorsal surface of the hind paw increased the spontaneous activity (2.54 ± 0.19 spikes/s, 25 minutes after the injection of formalin), frequency of excitation (35.37 ± 2.16 spikes/s, 25 minutes after the injection of formalin), and the duration of excitation (6.00 ± 0.091 s, 25 minutes after the injection of formalin) of spinal NS neurons as compared to baseline (0.042 ± 0.004 spikes/s, p = 0.031; 15.26 ± 0.32 spikes/s, p = 0.0065 and 2.3 ± 0.00 s, p < 0.0001 for the spontaneous activity, frequency of excitation, and duration of excitation, respectively) (Fig. 2). Administration of lebecetin (0.32 nmol, 30 μl) alone into the dorsal surface of the hind paw did not affect the spontaneous activity (0.22 ± 0.057 spike/s, p = 0.98), frequency of excitation (16.22 ± 0.32 spikes/s, p = 0.99), and duration of excitation (2.42 ± 0.04 s, p = 0.89) of spinal NS neurons 25 minutes after the administration of lebecetin as compared to the NS neuron activity of mice treated with vehicle (Fig. 2). When lebecetin (0.32 nmol, 30 μl) was administered 10 min before formalin, it significantly prevented the formalin-induced spinal hyperexcitability. Indeed 25 min after the administration of formalin, the spontaneous activity of spinal NS neurons was 0.21 ± 0.13 spike/s (p < 0.0001), the frequency of excitation was 16.37 ± 1.48 spikes/s (p < 0.0001), and the duration of excitation was 0.61 spikes/s (p <0.05), as compared to the NS neuron activity in mice receiving only formalin (Fig. 2C). Two-way ANOVA followed by Tukey’s post-hoc test revealed a significant effect of time (F(12, 143) = 32.33, p < 0.0001), treatment (F(3, 143) = 442.5, p < 0.0001) and a significant interaction time X treatment (F(36, 143) = 25.58, p < 0.0001), in the preventive effect of lebecetin. This effect was partially lost when lebecetin was administered 10 min after formalin administration. Indeed, it only slightly counteracted the sensitization of NS neurons found in the group of mice receiving formalin alone (Fig. 2). However, two-way ANOVA followed by Tukey’s post-hoc test revealed a significant effect of time (F(12, 143) = 7.265, p < 0.0001), treatment (F(3, 143) = 144.5, p < 0.0001) and a significant interaction time X treatment (F(36, 143) = 2.72, p < 0.0001), when lebecetin was injected after the formalin application. Finally, formalin-induced spinal hyperexcitability corresponded to a significant increase in amplitude (-1.46 ± 0.31 mV, p < 0.001) and slope (-2 ± 0.39 mV/ms, p < 0.001) of extracellular action potentials (eAPs), as compared to the vehicle-injected group of mice (-0.45 ± 0.15 mV for amplitude, and -0.95 ± 0.04 mV/ms for slope) (Fig. 2). The administration of lebecetin both before and after the injection of formalin was able to normalize the amplitude (-0.44 ± 0.09 mV, p < 0.001 for Lebe + Form, and -0.45 ± 0.1 mV, p < 0.001 for Form + Lebe) and slope (-0.86 ± 0.16 mV/ms, p < 0.001 for Lebe + Form, and -0.85 ± 0.24 mV/ms, p < 0.001 for Form + Lebe) (Fig. 2).

3.4 Effect of Lebecetin on the Expression Levels of Cytokines in the Spinal Cord

The levels of IL-1β, IL-4, IL-6, IL-8, IL-10, and TNF-α in the spinal cord and those of iNOS and COX2 in the serum and spinal cord were measured by ELISA assay.

A downward trend, even if not significant, in the expression levels of the anti-inflammatory cytokine IL-10 (99.21 ± 8.95, F(1,9) = 5.085, p = 0.0506) was found in the spinal cord of mice receiving the peripheral administration of formalin compared to the levels of IL-10 found in control mice (131.8 ± 14.54). An increasing trend, even if not significant, of IL-10, was found (165.0 ± 5.83, p = 0.056) in the spinal cord of mice receiving the lebecetin (0.32 nmol) into the hind paw. The levels of IL-10 in the spinal cord increased in mice treated with low doses of lebecetin (0.15 and 0.32 nmol) 10 min before the administration of formalin (207.1 ± 7.85, p < 0.0001 and 186.1 ± 6.21, p < 0.0001, respectively). The pretreatment with lebecetin at the doses of 0.64 and 1.31 nmol did not change the IL-10 levels in the spinal cord (126.8 ± 7.47 and 79.26 ± 13.99, respectively) (Fig. 3A).

The levels of the immunomodulatory cytokine, IL-4, were increased (3.75 ± 0.19, F(6,21) = 19.30, p < 0.0001) in the spinal cord of mice receiving the peripheral administration of formalin compared to control mice (2.64 ± 0.10). The levels of IL-4 did not change (3.14 ± 0.35) in the spinal cord of mice receiving the administration of lebecetin (0.32 nmol) into the hind paw. The levels of IL-4 in the spinal cord decreased (2.29 ± 0.16, p < 0.0001 and 3.0 ± 0.09, p < 0.04, respectively) in mice treated with low doses of lebecetin (0.15 and 0.32 nmol) 10 min before the administration of formalin. Also the dose of lebecetin of 0.64 nmol (30 μl) 10 min before formalin decreased IL-4 levels in the spinal cord (3.05 ± 0.12). The pretreatment with lebecetin 1.31 nmol did not reduce the IL-4 levels in the spinal cord (4.29 ± 1.99) (Fig. 3B).

The levels of IL-8, a chemotactic factor released by macrophages, did not change (129.8 ± 15.11) in the spinal cord of mice receiving the peripheral administration of formalin compared to control mice (114 ± 8.56). The levels of IL-8 were increased (243.4 ± 6.16) in the spinal cord of mice receiving the lebecetin (0.32 nmol) into the hind paw. The pretreatment with different doses of lebecetin (0.15, 0.32, 0.64, and 1.31 nmol) 10 min before the peripheral administration of formalin did not change the levels of IL-8 in the spinal cord (Fig. 3C).

The expression levels of IL-6 did not change (649.9 ± 15.96, F(6,21) = 9.74, p = 0.7352) in the spinal cord of mice receiving the peripheral administration of formalin compared to control mice (735.7 ± 15.96). The levels of IL-6 did not change (699.9 ± 24.96) also in the spinal cord of mice receiving the administration of lebecetin (0.32 nmol) into the hind paw. The pretreatment with lebecetin at the doses of 0.32 and 0.64 nmol, 10 min before the peripheral administration of formalin, decreased the levels of IL-6 (252 ± 32.52 and 424.9 ± 58.73, respectively) in the spinal cord (Fig. 3D). The doses of 0.15 and 1.31 nmol of lebecetin administered 10 min before the peripheral administration of formalin, were instead unable to change the IL-6 levels in the spinal cord (Fig. 3D).

The expression levels of the TNF-α increased (35.55 ± 4.34, F(6,14) = 289.8, p < 0.0001) in the spinal cord of mice treated with formalin compared to the levels of TNF-α in control mice (3.63 ± 0.464). The levels of TNF-α increased (201.6 ± 7.63) in the spinal cord of mice receiving the lebecetin (0.32 nmol) into the hind paw. The pretreatment with lebecetin (0.15 and 0.32 nmol) administered 10 min before the peripheral administration of formalin, did not change the TNF-α levels (26.40 ± 4.75 and 52.81 ± 2.52), while the levels of TNF-α in the spinal cord of mice receiving lebecetin at doses of 0.64 and 1.31 nmol were found greatly increased (138.1 ± 3.71 and 134.4 ± 3.20, p < 0.0001) (Fig. 3E).

The levels of the immunomodulatory cytokine IL-1β increased (39.92 ± 3.88, F(6,21) = 39.06; p < 0.0001) in the spinal cord of mice receiving the peripheral administration of formalin compared to control mice (16.34 ± 1.10). The levels of IL-1β increased (51.32 ± 1.87, p = 0.03) in the spinal cord of mice receiving the administration of lebecetin (0.32 nmol) into the hind paw. The levels of IL-1β were decreased by the pretreatment with the intermediate doses of lebecetin (0.32 and 0.64 nmol) 10 min before the peripheral administration of formalin (15.17 ± 2.13 and 18.67 ± 3.09, p < 0.0001). The pretreatment with the doses of 0.15 and 1.31 nmol of lebecetin, 10 min before the peripheral administration of formalin, did not change the IL-1β levels in the spinal cord (Fig. 3F).

3.5 Effect of Lebecetin on the Expression Levels of COX-2 and iNOS in the Serum and Spinal Cord

The peripheral administration of formalin did not change the levels of COX-2 in the serum (762.1 ± 21.85) (Fig. 4A), while it decreased the levels of COX-2 in the spinal cord (1261 ± 12.03, F(6,21) = 22.01; p < 0.0001) (Fig. 4B) compared to the levels found in the serum (546.9 ± 32.78) and spinal cord (1870 ± 59.93,) of control mice. The administration of lebecetin (0.32 nmol) alone did not change the levels of COX-2 in both the serum (792 ± 24.05) and spinal cord (1738 ± 66.91). The pretreatment with lebecetin (0.15, 0.32, 0.64, and 1.31 nmol) 10 min before the administration of formalin increased the expression levels of COX-2 in the serum (1392 ± 94.91, 5574 ± 157.5, 1201 ± 96.21, and 1220 ± 32.78, respectively) (Fig. 4A). Only the doses of 0.32 and 1.31 nmol of lebecetin increased the COX-2 expression levels in the spinal cord (1542 ± 92.76 and 1570 ± 78.42, respectively) (Fig. 4B).

The peripheral administration of formalin decreased the levels of i-NOS in the serum (2.59 ± 0.28 F(6,21) = 68.45, p < 0.0001) (Fig. 4C) and spinal cord (0.035 ± 0.006 F(6,21) = 18.65, p < 0.0001) (Fig. 4D) compared to the i-NOS expression levels in the serum (4.68 ± 0.29) and spinal cord (0.035 ± 0.006) of control mice. The administration of lebecetin (0.32 nmol) alone did not change the levels of i-NOS in the serum (3.80 ± 0.28) (Fig. 4C) while it decreased the i-NOS levels in the spinal cord (0 ± 0, p < 0.0001) (Fig. 4D). The pretreatment with lebecetin (0.15, 0.32, 0.64, and 1.31 nmol) 10 min before the peripheral administration of formalin increased the i-NOS expression levels in the serum (7.64 ± 0.09, 5.21 ± 0.0, ± 0.614 ± 0.09, and 5.21 ± 0.0 respectively) (Fig. 4C). Only the doses of 0.15 and 0.32 nmol of lebecetin administered 10 min before formalin increased the i-NOS levels in the spinal cord (0.06 ± 0 and 0.049 ± 0, respectively), while the doses of 0.64 and 1.31 were ineffective (Fig. 4D).

3.6 Effect of Lebecetin on Spinal Microglia Activation

The microglia component plays a pivotal role in the second phase of formalin-induced nocifensive behaviour. Indeed, it has been recently shown that spinal microglia contribute to sustained inflammatory pain via amplifying neuronal activity [27]. We found a significantly increased number of Iba1-positive microglia profiles in the dorsal horn of the spinal cord in the formalin-injected mice compared to the vehicle-injected control group (Fig. 5). Interestingly, the intra-paw injection of lebecetin (0.32 nmol), at the same dose that reduced the second phase of formalin-associated painful behavior, reduced the number of microglia cells.

3.7 Histopathological Changes Induced by Lebecetin in Formalin-associated Paw Inflammation

The skin biopsies of the dorsal paw showed marked cellular infiltration in the connective tissue with edema in both the epidermis and dermis. Formalin induced the appearance of diffuse spongy tissue swelling within the subcutaneously injected areas. The vascular diameter enlargement was observed which could be suggestive of a diffuse hyperemia around the vessels in the dermis. Moreover, lympho-monocytic infiltration was diffusely found in the epidermis and dermis. The biopsies from mice treated with lebecetin showed a partial reduction in the inflammatory response only with the lowest dose (0.32 nmol). The highest doses worsened the formalin-induced inflammatory state as inflammatory cells were more diffusely in number or near the vascular areas as compared to the formalin-injected group. Yet, lebecetin at the higher doses enhanced the subcutaneous tissue swelling and vascular diameter enlargement was larger as compared to the formalin group (Fig. 6).

4 DISCUSSION

Pain and inflammation are still not treated effectively and often remain unsolved clinical problems, especially after chronicization. The lack of corrective drugs to address these clinical issues could be directly related to the fact that the underlying mechanisms of chronic pain and inflammation are only partially understood, and the reported information is often conflicting [28]. The sensitization of the neurons involved in the transmission of nociceptive inputs is, in many cases, associated with the inflammatory cascade and the peripheral neurochemical alterations linked to the lesion of the nerve fibers. The formalin test, through the peripheral injection of a formalin-containing solution into the hind paw of mice, determines the development of both an acute proprioceptive inflammatory pain component and a late phase based on persistent sensitization (wind-up) of spinal neurons ipsilateral to the peripheral lesion [24]. In this study, we showed that the subcutaneous injection of lebecetin, a C-type lectin isolated from Macrovipera lebetina snake venom, inhibited in a dose-dependent, biphasic hormetic-like way the nocifensive reactions and the neuroinflammation-associated cytokine expression alterations induced by formalin. The hormetic pharmacological response manifests itself as a dose/response relationship characterized by a biphasic effect. In fact, in the presence of various chemical stimuli, biological tissue can give opposite responses depending on the doses. This means that a true dose-dependent biphasic response is determined, so much so that the hormesis could also be interpreted as a complex adaptive response aimed at survival or maintenance of homeostasis [29, 30]. In general, the responses presenting a hormetic trend are characterized by a modest stimulation of a certain function at low doses and by its subsequent inhibition (i.e., toxic) at increasing or higher doses.

4.1 Effect of Lebecetin on Formalin-induced Nocifensive Behaviour

Intra-paw lebecetin reduced nociceptive responses (and the paw thickness) in the first and second phase of the formalin test with only the lowest doses, while the higher doses partially reduced the second nociceptive phase without any effect on the first one. These biphasic behavioral effects by themselves suggest a dose-dependent hormetic action of lebecetin. Previous studies have demonstrated that the targets of lebecetin (as well as of lebectin and lebecin, which are isoforms of lebecetin) are certain integrins (i.e. α5β1 and αv) which are inhibited by both isoforms, thus preventing cell adhesion, platelet activation, and tumor cell migration/invasion [15-18]. Consequently, lebectin, lebecin, and lebecetin have the same inhibitory integrin pattern, interfering with the adhesion to fibronectin and fibrinogen, the major ligands for α5β1 and αv integrins. The described mechanism of action of lebecetin may partly explain its biphasic effect in reducing pain more effectively at low doses than at higher doses. Some αvβ3 and αvβ5 integrin inhibitors (proposed as possible anti-angiogenic drugs for cancer treatment) have been reported to exhibit a paradoxical effect at nanomolar doses: a facilitatory effect of angiogenesis and tumor growth rather than inhibiting the tumor growth [31]. Low concentrations of these agents could modify the structure of integrins and, therefore, the trafficking of angiogenesis promoters (i.e., VEGF) and/or cell adhesion receptors, thus favoring cell migration and survival [31]. A similar biphasic effect was observed with alternagin-C, a cysteine rich disintegrin of Rhinocerophis alternatus venom, on cardiomyocyte physiology. Treatment with this biomolecule produced a hormetic dose-response curve, a powerful inotropic effect and enhanced cardiac pumping capacity function at low doses, while a modest inotropism at higher doses [32]. The current study extends the effect of lebecetin by showing its capability of reducing the formalin-induced nocifensive behavior, the associated skin edema, and the spinal cord morpho-functional sequelae. The observed hormetic-like effect of lebecetin may be also due to the bi-directional activation of the cell signaling of the integrin. It can occur both as binding with the extracellular matrix (ECM), (i.e., cell adhesion and migration) in response to intracellular signals or activation of intracellular signals in response to ECM binding [33] and in the specific case of nociceptive signals, it can be directly related to the stimulation of dorsal root ganglia (DRG) neurons [34, 35]. Based on this, the ECM components play a decisive role in the genesis and maintenance of inflammation, cell recruitment, and the subsequent peripheral nerve sensitization in the inflamed tissue by the recruitment and activation of specific integrins [36]. The action of lebecetin for pain relieving may be attributable to its ability to block α5β1 or αv integrins. By avoiding the activation of integrins, it can prevent the downstream activation of receptors for inflammatory mediators (e.g., prostaglandin and/or bradykinin receptors, TRP channels, etc.) associated with nociceptive behavior in the formalin test.

The inhibitory action of lebecetin on integrins can prevent a massive and long-lasting recruitment/enhancement of ion channel activation through the mobilization of intracellular signaling proteins (e.g., G-protein components or kinases) [37]. Furthermore, the inhibition of intracellular calcium mobilization by lebecetin and the consequent failure to activate intracellular signaling pathways, such as PKCε [38, 39] or upregulation of COX2, PGE2 and activation of the adenylyl cyclase/cAMP/PKA cascade should also be strongly considered [39-41]. Therefore, we believe that the inhibition of α5β1 and αv integrins by lebecetin may prevent a complex series of intracellular signals responsible for the inhibition of nociceptive behavior. Furthermore, we observed that lebecetin at a low dose was not capable of inducing painful behavior by itself, showing no observed adverse effect level, NOEL. This indicates that the α5β1 and αv integrins may not have a tonic control effect on the sensitization of the nociceptive nerve or their discharges, but only in an inflamed environment (i.e., in the presence of elevated inflammatory mediators or by the recall of inflammatory cells). It is conceivable that cyclases, kinases, and many other enzymes involved in the signaling transduction leading to inflammation and hyperalgesia cooperate within a complex ECM-integrin-cytoskeleton interaction to orchestrate a signaling hub [42]. It has been shown that the β1 integrin subunit plays a role in hyperalgesia regardless of the type of chronic pain [22]. This subunit is expressed in various cell types, including immune cells, that play a key role in the development and maintenance of chronic pain [43, 44]. Indeed, a necessary function of immune cells for the chronicization of both inflammatory and neuropathic pain is now well recognized [43]. The selective involvement of integrins in lymphocyte activation and motility has been demonstrated in neuro-inflammatory conditions. Thus, integrin β1 subunit-deficient T lymphocytes drastically lose their ability to spread to nerve tissue in models of experimental autoimmune encephalopathy (EAE) in rodents, and this effect is associated with the found, delayed or abolished development of active EAE [45].

4.2 Effect of Lebecetin on Formalin-induced Gene Expression

Formalin increased the expression of the cytokines IL-1β, IL-4, and TNF-α in the spinal cord one hour after the intrapaw injection. This suggests that in our model of formalin-induced inflammation, these cytokines, compared to the others analyzed here (i.e., IL-6, IL-8, and IL-10),, participated more actively in the central maladaptive neuroplasticity involved in spontaneous pain and hyperalgesia induction. Furthermore, the fact that IL-4 expression is increased without a similar increase in IL-10, the other important anti-inflammatory cytokine, would suggest that IL-4 may assume a key compensatory function for local self-limiting neuroinflammation [46]. A predictably opposite trend was observed for gene expression of COX2 and iNOS, two key enzymes with a cellular protective function. Down-regulation of these two enzymes by intra-paw formalin (mainly by iNOS and partly by COX2) was observed in the spinal cord, and lower doses of lebecetin then reversed this effect. Consistently, the same recovery trend was found in serum for those enzymes. This indicates that although formalin damage is localized (i.e., paw), the change in the expression of cytokines, COX2, and iNOS affects different tissues or organs at a distance (spinal cord and blood). Thus, our data confirm that pathological pain is a systemic clinical condition rather than a problem confined exclusively to a single organ district. As observed with COX2 and iNOS, cytokine levels were also shifted towards more physiological values with lower doses of lebecetin. As mentioned above, such a dose-dependent hormetic-like effect of lebecetin was also observed in ameliorating pain or paw edema. Although our experiments do not allow us to understand why a greater pain-killer effect was observed at lower doses, here we may hypothesize different binding affinities on different integrins, e.g., α5β involved in the production of PGE2 [22], playing opposite roles in the induction of inflammatory cascades, or even the loss of selectivity at higher doses of lebecetin leading to the activation of other integrin receptors/pathways that can facilitate the inflammatory process and pain responses [47, 48]. In fact, it should be borne in mind that stimulation of lectin C receptors activates a complex immune response that models specific responses to any antigen [49]. It may be supposed that with increasing doses, lebecetin stimulates its own receptors (both membrane and cytosolic), which, by regulating NFkB in various ways (i.e., signaling through SyK and RAF1 to direct cytokine expression pattern), induce different phenotypes of antigen-presenting cells to differentiate, in turn, in several lymphocyte clones [50]. Thereafter, different clones of T lymphocytes produce various cytokines to organize a precise immune response. In this study, a gradual loss of the analgesic and anti-inflammatory effect with higher doses of lebecetin might be, therefore, conceivable following activation of the lectin receptors with consequent masking or occlusion of the protective effects by blocking the α5β1 and αv integrins with lower doses.

A confirmation that the blockade of those integrins may inhibit the synthesis of pro-inflammatory cytokines and instead increase the anti-inflammatory ones has been recently shown in vitro on macrophages derived from human monocytic THP1 cells exposed to LPS [21]. This multi-receptor activity of lebecetin could also explain why this biomolecule (at least at the best-protecting dose in this study) per se increased the expression of some inflammatory cytokines and reduced iNOS in healthy conditions. This apparently paradoxical defect may be linked to the very nature of a molecule that, by interfering with the immune system and its role in continuous functional adaptation, can exert pleiotropic effects, which are often opposite depending on a given pathophysiological context [51]. Thus, there is evidence that a well-studied C-type lectin receptor, Dectin-1 [52], depending on how different ligands in the surrounding environment may vary, may perform even opposite activities in immune regulation. In addition to pro-inflammatory responses, such as cytokine production and phagocytosis, tolerant responses have also been attributed to dectin-1 activation [53].

4.3 Effect of Lebecetin on Formalin-induced NS Neuron Hyperactivity

In this study, formalin caused a marked increase in the spontaneous activity, frequency, and duration of excitation of spinal NS neurons. Formalin also increased both the amplitude and slope of NS neurons. The amplitude and slope of APs correlate with synaptic strength, the magnitude of the synaptic currents and the number of activated input fibers of NS neurons [54]. Overall, the spinal sensitization following peripheral formalin administration that overlaps and underlies the nociceptive behavior has been widely reported [55-58]. What is noteworthy is the fact that even if lebecetin alone had no effect on the activity of spinal NS neurons, when administered before formalin and exactly 10 min before, it abolished the hyperactivity of spinal NS neurons, thus showing a neuroprotective effect. Intriguingly, the administration of lebecetin after the administration of formalin was able to normalize the NS neuron hyperactivation. The sensitization of spinal neurons is inevitably associated with the peripheral inflammatory cascade and neurochemical alterations induced by the peripheral administration of formalin, but even more, it is the expression of an altered local microenvironment, which, as described above, undergoes modifications in the expression of enzymes and cytokines involved in inflammatory processes. Therefore, the inhibitory effect of lebecetin on the spinal inflammatory microenvironment could also underlie the functional effects of NS neuron activity. Moreover, lebecetin showed effectiveness not only as a preventive treatment but also for overt neuroinflammation when administered after formalin. Although more in-depth experiments aimed at investigating the mechanisms underlying the effects of lebecetin on the activity of NS spinal neurons hyperactivated by formalin are required, we believe this preliminary data is interesting because it highlights a neuroprotective effect of lebecetin which may be useful in restoring neurofunctional alterations underlying chronicization of pain.

4.4 Effect of Lebecetin on Formalin-induced Microglia Activation

Finally, it has been recently demonstrated that spinal microglia contribute to sustained inflammatory pain via amplifying neuronal activity. In particular, spinal microglia activation seems to be associated with increased neuronal excitability. Indeed, the depletion of resident microglia cells reduced neuronal hyperactivity in the second phase of formalin-induced tonic pain [27]. Here, we confirmed the increased microglia proliferation in the superficial laminae of the dorsal horn of the spinal cord. Consistently, with the behavioral and functional data of electrophysiology, we found that the 0.32 nmol dose of lebecetin significantly reduced the microglia cell number in the same area. The microglial immune-driven component of the tonic phase of formalin also affected the infiltrating inflammatory cells in the hind paw skin, which were significantly reduced in microglia-depleted mice [27]. Consistently, we also found that the formalin-injected mice showed a dishomogeneous tissue in terms of dermal structures and collagen, together with an enhancement of infiltrating cells. These observational histological data also revealed that the dose of 0.32 nmol of lebecetin reduced both the morphological architecture impairments and the inflammatory reaction. Conversely, the higher doses of lebecetin worsened the tissue impairments induced by the formalin injection, assuming a hormetic/biphasic effect of this natural protein venom.

CONCLUSION

This study further underlines the role of C-type lectins in the complex regulation of several cellular functions. This complexity is a consequence of the variable and extreme adaptability of their intracellular signaling activity under physiological or pathological conditions. In this study, we hypothesize that lebecetin, at higher doses, may act on the C-type lectin receptors (CLRs), which will be interesting to identify, while at lower doses, it more selectively inhibits some integrins (α5β1 and αv integrins). The outcome of the signals triggered by integrins and CLR, or their functional interaction, depends not only on these receptor systems but also on the nature or density of many other co-present ligands. Indeed, the microenvironment in which these protein/protein interactions occur plays a crucial role in one functional outcome rather than another. The inflammatory environment and the simultaneous presence of many other mediators at work is a very different condition from healthy tissue physiology. Therefore any biological or pharmacological alterations can also be very different. We can therefore imagine for lebecetin, and more generally for lectins, that they can have a versatile action and perform a multitude of functional adaptations to preserve the functional integrity of tissues and, in general, to maintain cellular homeostasis. Consequently, the protein-protein interaction between lebecetin and CSF and/or integrins within the extracellular matrix may be critical in shutting down the signaling systems that mediate inflammation and hyperalgesia. These findings further encourage the search for new targets and improved associated therapies against inflammatory pain.

ACKNOWLEDGEMENTS

Declared none.

LIST OF ABBREVIATIONS

CLRs C-type Lectin Receptors

DRG Dorsal Root Ganglia

eAPs Extracellular Action Potentials

ECM Extracellular Matrix

NS Nociceptive-specific

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study was approved by the Animal Ethics Committee of the University of Campania “L. Vanvitelli.

HUMAN AND ANIMAL RIGHTS

All animal care procedures were complied with Italian (D.L. 116/92) and EEC (O.J. of E.C. L358/1 18/12/86) regulations on the protection of laboratory animals.

CONSENT FOR PUBLICATION

Not applicable.

AVAILABILITY OF DATA AND MATERIALS

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

SUPPLEMENTARY MATERIAL

Supplementary material is available on the publisher’s website along with the published article.

Fig. (1) (A) shows the effect of vehicle (Veh, PBS 1%, 30 μl) or different doses of lebecetin (Lebe, 0.15, 0.32, 0.64, and 1.31 nmol in 30 μl) administered in the dorsal surface of the hind paw 10 min before formalin (Form, 1.25%, 30 μl) on the nocifensive response expressed in min. (B) shows the dose-response curve (hormesis) of Lebecetin built on the pro/antinociceptive response in formalin-injected mice. The responses obtained at different nmol doses were normalized to the maximum antinociceptive effect (0.32 nmol). (C) shows the effect of vehicle (Veh, PBS 1%, (30 μl), formalin (Form, 1.25%, 30 μl), lebecetin (Lebe, 0.32 nmol, 30 μl), or different doses of lebecetin (Lebe, 0.15, 0.32, 0.64, and 1.31 in 30 μl)) administered in the dorsal surface of the hind paw 10 min before formalin (Form, 1.25%, 30 μl) on paw thickness expressed in mm and photographs showing hind paw edema after subcutaneous injection of formalin (Form) and ameliorative effect after pretreatment (10 min before formalin) with different lebecetin doses (Lebe, 0.15, 0.32, 0.64, and 1.31 nmol). Each time point represents the mean ± SEM of 5-10 (A) or 3 (C) mice per group. p < 0.05 was considered statistically significant, two-way ANOVA followed by Dunnet's post-hoc test (A) and one-way ANOVA followed by Dunnett’s post-hoc test (C). Filled symbols indicate statistically significant time points in panel A. # indicates p < 0.05 vs. vehicle-injected mice, and ****p < 0.001 vs. formalin-injected mice in panel C.

Fig. (2) Representative ratematers showing the spontaneous and noxious-evoked activity of spinal NS neurons before (baseline) and after the subcutaneous administration of vehicle (PBS 1%) 10 min before formalin (Form, 1.25%, 30 μl) (A) or lebecetin (0.32 nmol, 30 μl) (B) in the dorsal surface of the hind paw. (C) shows representative ratematers showing the spontaneous (baseline) and noxious-evoked activity of spinal NS neurons before and after the subcutaneous administration of lebecetin (0.32 nmol, 30 μl) 10 min before formalin (Form, 1.25%, 30 μl) whereas (D) shows representative ratematers showing the spontaneous and noxious-evoked activity of spinal NS neurons before (baseline), and after the subcutaneous administration of formalin (Form, 1.25%, 30 μl) 10 min before lebecetin (0.32 nmol, 30 μl). Effect of the subcutaneous administration of vehicle (Veh, PBS 1%, 30 μl), formalin (Form, 1.25%, 30 μl), lebecetin (Lebe, 0.32 nmol, 30 μl) or lebecetin (0.32 nmol, 30 μl) administered 10 min before formalin on the firing rate (E), frequency of excitation (F), and duration of excitation (G). Effect of the administration of vehicle (Veh, PBS 1%, 30 μl), formalin (Form, 1.25%, 30 μl), lebecetin (Lebe, 0.32 nmol, 30 μl), lebecetin administered 10 min before formalin (Lebe/Form), and lebecetin administered 10 min after formalin (Form/Lebe) on the amplitude (mV) of spinal NS neurons (H). The effect of the subcutaneous administration of vehicle (Veh, PBS 1%), formalin (Form, 1.25%, 30 μl) or lebecetin (Leb, 0.32 nmol, 30 μl) on the firing rate (I), frequency of excitation (J), and duration of excitation (K) was also evaluated when lebecetin (0.32 nmol, 30 μl) was administered 10 min after formalin. Effect of the administration of vehicle (Veh, PBS 1%, 30 μl), formalin (Form, 1.25%, 30 μl), lebecetin (Lebe, 0.32 nmol, 30 μl), lebecetin administered 10 min before formalin (Lebe/Form), and lebecetin administered 10 min after formalin (Form/Lebe) on the slope (mV/ms) (L) of spinal NS neurons. Each point represents the mean ± S.E.M. ***indicates p < 0.005 vs. vehicle, ##indicates p < 0.01, and ###p < 0.005 vs. form (two-way ANOVA followed by Tukey’s post-hoc test).

Fig. (3) Effect of vehicle (Veh, PBS 1%, 30 μl), formalin (Form, 1.25%, 30 μl), lebecetin (Lebe, 0.32 nmol, 30 μl) or different doses of lebecetin (Lebe, 0.15, 0.32, 0.64, and 1.31 nmol in 30 μl) administered in the dorsal surface of the hind paw 10 min before formalin on cytokines levels expressed in pg/ml in the spinal cord. In particular, the effects of the above treatments on IL-10 (A), IL-4 (B), IL-8 (C), IL-6 (D), TNF-α (E), and IL-1β (F) are shown. Each histogram represents the mean ± SEM of 4 mice per group. p < 0.05 was considered statistically significant (one-way ANOVA followed by Dunnett’s post-hoc test). #indicates p < 0.05, ###p < 0.005, and ####p < 0.001 vs. vehicle-injected mice. *indicates p < 0.05, ***p < 0.005, and ****p < 0.001 vs. formalin-injected mice.

Fig. (4) Effect of vehicle (Veh, PBS 1%, 30 μl), formalin (Form, 1.25%, 30 μl), lebecetin (Lebe, 0.32 nmol, 30 μl) or different doses of lebecetin (Lebe, 0.15, 0.32, 0.64, and 1.31 nmol in 30 μl) administered in the dorsal surface of the hind paw 10 min before formalin on COX-2 (A and B) and i-NOS (C and D) levels expressed in pg/ml in the serum (A and C) and spinal cord (B and D). Each histogram represents the mean ± SEM of 3-4 mice per group. P < 0.05 was considered statistically significant (one-way ANOVA followed by Dunnett’s post-hoc test). #indicates p < 0.05, ###p < 0.005 and ####p < 0.001 vs. vehicle-injected mice. *indicates p < 0.05, **p < 0.01, ***p < 0.005, and ****p < 0.001 vs. formalin-injected mice.

Fig. (5) Effect of vehicle (Veh, PBS 1%, 30 μl) or lebecetin (Lebe, 0.32 nmol, 30 μl) administered in the dorsal surface of the hind paw 10 min before formalin (Form, 1.25%, 30 μl) on Iba-1 immunoreactivity (Iba-1-ir) in the dorsal horns of the spinal cord (A). Quantitative analysis of spinal cord sections shows increased numbers of Iba-1 positive microglia in the dorsal horn of spinal cord in mice receiving vehicle 10 min before the administration of formalin compared to control mice. Lebecetin (0.32 nmol, 30 μl), administered 10 min before formalin into the dorsal surface of the hind paw significantly reduced the number of the Iba-1 positive profiles (B). Data represent mean ± S.E.M., n = 3 mice per group. p < 0.05 was considered statistically significant. ##indicates p < 0.01 versus control mice, whereas ° indicates p < 0.05 versus formalin-injected mice, one-way ANOVA followed by Tukey’s post hoc test. Scale bars = 500, 100, 50 um in the low magnification, medium magnification and inset, respectively.

Fig. (6) Representative photographs from the skin show the protective effect of lebecetin against formalin-induced inflammation and edema in dorsal paw skin (H&E stain) in mice. (a) Control; (b) formalin + vehicle; (c) formalin + lebecetin 0.32 nmol; (d) formalin +lebecetin 0.64 nmol; (e) formalin + lebecetin 1.31 nmol.
==== Refs
REFERENCES

1 del Río-Portilla F. Hernández-Marín E. Pimienta G. Coronas F.V. Zamudio F.Z. Rodríguez de la Vega R.C. Wanke E. Possani L.D. NMR solution structure of Cn12, a novel peptide from the Mexican scorpion Centruroides noxius with a typical beta-toxin sequence but with alpha-like physiological activity. Eur. J. Biochem. 2004 271 12 2504 2516 10.1111/j.1432-1033.2004.04181.x 15182366
2 Rodríguez de la Vega R.C. Possani L.D. Current views on scorpion toxins specific for K+-channels. Toxicon 2004 43 8 865 875 10.1016/j.toxicon.2004.03.022 15208019
3 Patil C.G. Walker D.G. Miller D.M. Butte P. Morrison B. Kittle D.S. Hansen S.J. Nufer K.L. Byrnes-Blake K.A. Yamada M. Lin L.L. Pham K. Perry J. Parrish-Novak J. Ishak L. Prow T. Black K. Mamelak A.N. Phase 1 safety, pharmacokinetics, and fluorescence imaging study of Tozuleristide (BLZ-100) in adults with newly diagnosed or recurrent gliomas. Neurosurgery 2019 85 4 E641 E649 10.1093/neuros/nyz125 31069381
4 McDermott A. Venom back in vogue as a wellspring for drug candidates. Proc. Natl. Acad. Sci. USA 2020 117 19 10100 10104 10.1073/pnas.2004486117 32321825
5 Pucca M.B. Peigneur S. Cologna C.T. Cerni F.A. Zoccal K.F. Bordon K.C.F. Faccioli L.H. Tytgat J. Arantes E.C. Electrophysiological characterization of the first Tityus serrulatus alpha-like toxin, Ts5: Evidence of a pro-inflammatory toxin on macrophages. Biochimie 2015 115 8 16 10.1016/j.biochi.2015.04.010 25906692
6 Jiménez-Vargas J.M. Restano-Cassulini R. Possani L.D. Toxin modulators and blockers of hERG K+ channels. Toxicon 2012 60 4 492 501 10.1016/j.toxicon.2012.03.024 22497787
7 Cerni F.A. Pucca M.B. Amorim F.G. de Castro Figueiredo Bordon K. Echterbille J. Quinton L. De Pauw E. Peigneur S. Tytgat J. Arantes E.C. Isolation and characterization of Ts19 Fragment II, a new long-chain potassium channel toxin from Tityus serrulatus venom. Peptides 2016 80 9 17 10.1016/j.peptides.2015.06.004 26116782
8 Siigur J. Aaspõllu A. Siigur E. Biochemistry and pharmacology of proteins and peptides purified from the venoms of the snakes Macrovipera lebetina subspecies. Toxicon 2019 158 16 32 10.1016/j.toxicon.2018.11.294 30472110
9 Bazaa A. Luis J. Srairi-Abid N. Kallech-Ziri O. Kessentini-Zouari R. Defilles C. Lissitzky J.C. El Ayeb M. Marrakchi N. MVL-PLA2, a phospholipase A2 from Macrovipera lebetina transmediterranea venom, inhibits tumor cells adhesion and migration. Matrix Biol. 2009 28 4 188 193 10.1016/j.matbio.2009.03.007 19351557
10 Zouari-Kessentini R. Luis J. Karray A. Kallech-Ziri O. Srairi-Abid N. Bazaa A. Loret E. Bezzine S. El Ayeb M. Marrakchi N. Two purified and characterized phospholipases A2 from Cerastes cerastes venom, that inhibit cancerous cell adhesion and migration. Toxicon 2009 53 4 444 453 10.1016/j.toxicon.2009.01.003 19708222
11 Baîram D. Aissa I. Louati H. Othman H. Abdelkafi-Koubaa Z. Krayem N. El Ayeb M. Srairi-Abid N. Marrakchi N. Gargouri Y. Biochemical and monolayer characterization of Tunisian snake venom phospholipases. Int. J. Biol. Macromol. 2016 89 640 646 10.1016/j.ijbiomac.2016.05.020 27164498
12 Morjen M. Othman H. Abdelkafi-Koubaa Z. Messadi E. Jebali J. El Ayeb M. Abid N.S. Luis J. Marrakchi N. Targeting α1 inserted domain (I) of α1β1 integrin by Lebetin 2 from M. lebetina transmediterranea venom decreased tumorigenesis and angiogenesis. Int. J. Biol. Macromol. 2018 117 790 799 10.1016/j.ijbiomac.2018.05.230 29870815
13 Gasmi A. Srairi N. Guermazi S. Dkhil H. Karoui H. El Ayeb M. Amino acid structure and characterization of a heterodimeric disintegrin from Vipera lebetina venom. Biochim. Biophys. Acta Protein Struct. Mol. Enzymol. 2001 1547 1 51 56 10.1016/S0167-4838(01)00168-6 11343790
14 Jebali J. Bazaa A. Sarray S. Benhaj K. Karboul A. El Ayeb M. Marrakchi N. Gargouri A. C-type lectin protein isoforms of Macrovipera lebetina: cDNA cloning and genetic diversity. Toxicon 2009 53 2 228 237 10.1016/j.toxicon.2008.11.006 19059426
15 Sarray S. Berthet V. Calvete J.J. Secchi J. Marvaldi J. Ayeb M.E. Marrakchi N. Luis J. Lebectin, a novel C-type lectin from Macrovipera lebetina venom, inhibits integrin-mediated adhesion, migration and invasion of human tumour cells. Lab. Invest. 2004 84 5 573 581 10.1038/labinvest.3700088 15048137
16 Jebali J. Fakhfekh E. Morgen M. Srairi-Abid N. Majdoub H. Gargouri A. El Ayeb M. Luis J. Marrakchi N. Sarray S. Lebecin, a new C-type lectin like protein from Macrovipera lebetina venom with anti-tumor activity against the breast cancer cell line MDA-MB231. Toxicon 2014 86 16 27 10.1016/j.toxicon.2014.04.010 24814013
17 Sarray S. Delamarre E. Marvaldi J. Ayeb M.E. Marrakchi N. Luis J. Lebectin and lebecetin, two C-type lectins from snake venom, inhibit α5β1 and αv-containing integrins. Matrix Biol. 2007 26 4 306 313 10.1016/j.matbio.2007.01.001 17300927
18 Sarray S. Srairi N. Hatmi M. Luis J. Louzir H. Regaya I. Slema H. Marvaldi J. El Ayeb M. Marrakchi N. Lebecetin, a potent antiplatelet C-type lectin from Macrovipera lebetina venom. Biochim. Biophys. Acta. Proteins Proteomics 2003 1651 1-2 30 40 10.1016/S1570-9639(03)00232-2 14499586
19 Sarray S. Srairi N. Luis J. Marvaldi J. El Ayeb M. Marrakchi N. Lebecetin, a C-lectin protein from the venom of Macrovipera lebetina that inhibits platelet aggregation and adhesion of cancerous cells. Haemostasis 2001 31 3-6 173 176 11910182
20 Montassar F. Darche M. Blaizot A. Augustin S. Conart J.B. Millet A. Elayeb M. Sahel J.A. Goazigo A.R-L. Sennlaub F. Marrakchi N. Messadi E. Guillonneau X. Lebecetin, a C-type lectin, inhibits choroidal and retinal neovascularization. FASEB J. 2017 31 3 1107 1119 10.1096/fj.201600351R 27974593
21 Jebali J. Zakraoui O. Aissaoui D. Abdelkafi-Koubaa Z. Srairi-Abid N. Marrakchi N. Essafi-Benkhadir K. Lebecetin, a snake venom C-type lectin protein, modulates LPS-induced inflammatory cytokine production in human THP-1-derived macrophages. Toxicon 2020 187 144 150 10.1016/j.toxicon.2020.09.001 32918926
22 Dina O.A. Parada C.A. Yeh J. Chen X. McCarter G.C. Levine J.D. Integrin signaling in inflammatory and neuropathic pain in the rat. Eur. J. Neurosci. 2004 19 3 634 642 10.1111/j.1460-9568.2004.03169.x 14984413
23 Hunskaar S. Hole K. The formalin test in mice: Dissociation between inflammatory and non-inflammatory pain. Pain 1987 30 1 103 114 10.1016/0304-3959(87)90088-1 3614974
24 Tjølsen A. Berge O.G. Hunskaar S. Rosland J.H. Hole K. The formalin test: An evaluation of the method. Pain 1992 51 1 5 17 10.1016/0304-3959(92)90003-T 1454405
25 Tjolsen A. Hole K. Animal models of analgesia. The Pharmacology of Pain Dickenson A. Besson J. Springer Verlag Berlin 1997 30 1 20 10.1007/978-3-642-60777-6_1
26 Coderre T.J. Melzack R. The role of NMDA receptor-operated calcium channels in persistent nociception after formalin-induced tissue injury. J. Neurosci. 1992 12 9 3671 3675 10.1523/JNEUROSCI.12-09-03671.1992 1326611
27 Gu N. Yi M.H. Murugan M. Xie M. Parusel S. Peng J. Eyo U.B. Hunt C.L. Dong H. Wu L.J. Spinal microglia contribute to sustained inflammatory pain via amplifying neuronal activity. Mol. Brain 2022 15 1 86 10.1186/s13041-022-00970-3 36289499
28 Schaible H.G. Richter F. Pathophysiology of pain. Langenbecks Arch. Surg. 2004 389 4 237 243 10.1007/s00423-004-0468-9 15034717
29 Demirovic D. Rattan S.I.S. Establishing cellular stress response profiles as biomarkers of homeodynamics, health and hormesis. Exp. Gerontol. 2013 48 1 94 98 10.1016/j.exger.2012.02.005 22525591
30 Schirrmacher V. Less can be more: The hormesis theory of stress adaptation in the global biosphere and its implications. Biomedicines 2021 9 3 293 10.3390/biomedicines9030293 33805626
31 Reynolds A.R. Hart I.R. Watson A.R. Welti J.C. Silva R.G. Robinson S.D. Da Violante G. Gourlaouen M. Salih M. Jones M.C. Jones D.T. Saunders G. Kostourou V. Perron-Sierra F. Norman J.C. Tucker G.C. Hodivala-Dilke K.M. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med. 2009 15 4 392 400 10.1038/nm.1941 19305413
32 Monteiro D.A. Kalinin A.L. Selistre-de-Araujo H.S. Rantin F.T. Hormetic-like dose-response induced by alternagin-C, a protein isolated from urutu snake (Rhinocerophis alternatus) venom, in fish (Hoplias malabaricus) cardiac contractility. Toxicon 2022 205 67 70 10.1016/j.toxicon.2021.11.123 34838810
33 Miranti C.K. Brugge J.S. Sensing the environment: A historical perspective on integrin signal transduction. Nat. Cell Biol. 2002 4 4 E83 E90 10.1038/ncb0402-e83 11944041
34 Andrew S.M. Edwards B.D. Chalmers R.J.G. O’Driscoll J.B. A quantitative immunohistochemical study of the expression of integrins by nerves in psoriatic and normal skin. Br. J. Dermatol. 1992 127 4 359 364 10.1111/j.1365-2133.1992.tb00454.x 1419755
35 Tomaselli K.J. Doherty P. Emmett C.J. Damsky C.H. Walsh F.S. Reichardt L.F. Expression of beta 1 integrins in sensory neurons of the dorsal root ganglion and their functions in neurite outgrowth on two laminin isoforms. J. Neurosci. 1993 13 11 4880 4888 10.1523/JNEUROSCI.13-11-04880.1993 7693896
36 Catalina M.D. Estess P. Siegelman M.H. Selective requirements for leukocyte adhesion molecules in models of acute and chronic cutaneous inflammation: participation of E and P but not L-selectin. Blood 1999 93 2 580 589 10.1182/blood.V93.2.580 9885219
37 Giancotti F.G. Ruoslahti E. Integrin Signaling. Science 1999 285 5430 1028 1033 10.1126/science.285.5430.1028 10446041
38 Berrier A.L. Mastrangelo A.M. Downward J. Ginsberg M. LaFlamme S.E. Activated R-ras, Rac1, PI 3-kinase and PKCepsilon can each restore cell spreading inhibited by isolated integrin beta1 cytoplasmic domains. J. Cell Biol. 2000 151 7 1549 1560 10.1083/jcb.151.7.1549 11134082
39 Sachs D. Villarreal C.F. Cunha F.Q. Parada C.A. Ferreira S.H. The role of PKA and PKCε pathways in prostaglandin E2-mediated hypernociception. Br. J. Pharmacol. 2009 156 5 826 834 10.1111/j.1476-5381.2008.00093.x 19220288
40 Suzuki K. Grinnell A.D. Kidokoro Y. Hypertonicity-induced transmitter release at Drosophila neuromuscular junctions is partly mediated by integrins and cAMP/protein kinase A. J. Physiol. 2002 538 1 103 119 10.1113/jphysiol.2001.012901 11773320
41 Dormond O. Bezzi M. Mariotti A. Rüegg C. Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J. Biol. Chem. 2002 277 48 45838 45846 10.1074/jbc.M209213200 12237321
42 Geiger B. Bershadsky A. Pankov R. Yamada K.M. Transmembrane crosstalk between the extracellular matrix and the cytoskeleton. Nat. Rev. Mol. Cell Biol. 2001 2 11 793 805 10.1038/35099066 11715046
43 Marchand F. Perretti M. McMahon S.B. Role of the Immune system in chronic pain. Nat. Rev. Neurosci. 2005 6 7 521 532 10.1038/nrn1700 15995723
44 Baral P. Udit S. Chiu I.M. Pain and immunity: Implications for host defence. Nat. Rev. Immunol. 2019 19 7 433 447 10.1038/s41577-019-0147-2 30874629
45 Bauer M. Brakebusch C. Coisne C. Sixt M. Wekerle H. Engelhardt B. Fässler R. β 1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity. Proc. Natl. Acad. Sci. USA 2009 106 6 1920 1925 10.1073/pnas.0808909106 19179279
46 He Y. Gao Y. Zhang Q. Zhou G. Cao F. Yao S. IL-4 switches microglia/macrophage M1/M2 polarization and alleviates neurological damage by modulating the JAK1/STAT6 pathway following ICH. Neuroscience 2020 437 161 171 10.1016/j.neuroscience.2020.03.008 32224230
47 Cam A. de Mejia E.G. RGD-peptide lunasin inhibits Akt-mediated NF-κB activation in human macrophages through interaction with the αVβ3 integrin. Mol. Nutr. Food Res. 2012 56 10 1569 1581 10.1002/mnfr.201200301 22945510
48 Peng S. Jia J. Sun J. Xie Q. Zhang X. Deng Y. Yi L. LXW7 attenuates inflammation via suppressing Akt/nuclear factor kappa B and mitogen-activated protein kinases signaling pathways in lipopolysaccharide-stimulated BV2 microglial cells. Int. Immunopharmacol. 2019 77 105963 10.1016/j.intimp.2019.105963 31732449
49 Geijtenbeek T.B.H. Gringhuis S.I. Signalling through C-type lectin receptors: Shaping immune responses. Nat. Rev. Immunol. 2009 9 7 465 479 10.1038/nri2569 19521399
50 Gringhuis S.I. den Dunnen J. Litjens M. van der Vlist M. Wevers B. Bruijns S.C.M. Geijtenbeek T.B.H. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-κB activation through Raf-1 and Syk. Nat. Immunol. 2009 10 2 203 213 10.1038/ni.1692 19122653
51 Sancho D. Reis e Sousa C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu. Rev. Immunol. 2012 30 1 491 529 10.1146/annurev-immunol-031210-101352 22224766
52 Mata-Martínez P. Bergón-Gutiérrez M. del Fresno C. Dectin-1 signaling update: New perspectives for trained immunity. Front. Immunol. 2022 13 812148 10.3389/fimmu.2022.812148 35237264
53 Geijtenbeek T.B.H. Gringhuis S.I. C-type lectin receptors in the control of T helper cell differentiation. Nat. Rev. Immunol. 2016 16 7 433 448 10.1038/nri.2016.55 27291962
54 Bliss T.V.P. Collingridge G.L. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 1993 361 6407 31 39 10.1038/361031a0 8421494
55 Dickenson A.H. Sullivan A.F. Subcutaneous formalin-induced activity of dorsal horn neurones in the rat: Differential response to an intrathecal opiate administered pre or post formalin. Pain 1987 30 3 349 360 10.1016/0304-3959(87)90023-6 3670880
56 Haley J.E. Dickenson A.H. Schachter M. Electrophysiological evidence for a role of bradykinin in chemical nociception in the rat. Neurosci. Lett. 1989 97 1-2 198 202 10.1016/0304-3940(89)90163-8 2537479
57 Haley J. Ketchum S. Dickenson A. Peripheral κ-opioid modulation of the formalin response: An electrophysiological study in the rat. Eur. J. Pharmacol. 1990 191 3 437 446 10.1016/0014-2999(90)94178-Z 1964910
58 Sullivan A.F. Dickenson A.H. Roques B.P. δ-Opioid mediated inhibitions of acute and prolonged noxious-evoked responses in rat dorsal horn neurones. Br. J. Pharmacol. 1989 98 3 1039 1049 10.1111/j.1476-5381.1989.tb14636.x 2556199
